AbCellera Biologics Inc. ABCL Receipt of grant funding
Receipt of grant funding at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept abcl:ProceedsFromReceiptOfGrantFunding.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s receipt of grant funding.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s receipt of grant funding?
- AbCellera Biologics Inc. (ABCL) reported receipt of grant funding of $1.36M in Q1 2026.
- How has AbCellera Biologics Inc.'s receipt of grant funding changed year-over-year?
- AbCellera Biologics Inc.'s receipt of grant funding increased by 33.7% year-over-year, from $1.02M to $1.36M.
- What is the long-term trend for AbCellera Biologics Inc.'s receipt of grant funding?
- Over 3 years (2022 to 2025), AbCellera Biologics Inc.'s receipt of grant funding has grown at a 9.1% compound annual growth rate (CAGR), from $16.43M to $21.34M.
- What does receipt of grant funding mean?
- This captures the cash inflows received from government or private entities specifically designated for research and development initiatives. Unlike revenue, these funds are typically non-dilutive and support the company's platform development. It is a key indicator of the company's ability to secure external non-equity financing for its scientific pipeline.